Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma

Background: Endometrial cancer (EC) is the most common pelvic gynecological cancer. The purpose of the present study is to identify histoprognostic risk factors for lymph node involvement, evaluate the impact of lymphadenectomy on relapse and overall survival and assess prognostic factors influencing the survival rates in endometrial cancer.Methods: This was a retrospective study of 249 cases of endometrial cancer, over a period of 16 years (2000-2015). We analyzed the clinical, pathological features and outcome of our patients. Curves of overall and recurrence-free survival were performed.Results: In our cohort, stage IA was found in 46.6% of cases, stage IB in 14.5%, stage II in 13.7%, stage IIIA in 3.6%, stage IIIB in 2%, stage IIIC1 in 8.8%, stage IIIC2 in 4.4% and stage IV in 6.4%. The histologic type (p=0.02, OR=2.702, CI [1.169; 6.25]), myometrial invasion (p<0.001, OR=4.524, CI [1.960; 10.416]), lymphovascular space invasion (p=0.047, OR=2.267; CI [1.013; 5.076]) were the only independent factors of lymph node invasion in multivariate analysis. 5-years overall and recurrence free survival was 76.3% and 81.5%, respectively. Overall survival at 5 years was 64.6% with a lymph node ratio of less than 10%, 22.2% with a lymph node ratio between 10 and 50%, and zero with a lymph node ration greater than 50% (p=0.016). By studying the number of lymph nodes removed during lymphadenectomy, survival trend to be improved when the lymph node count increased.Conclusions: The lymphadenectomy has an incontestable diagnostic and prognostic value. Present retrospective study showed the therapeutic interest of lymph node dissection in endometrial cancers.

Download Full-text

Hepatic Artery Lymph Node in Pancreatic Cancer: A Retrospective Analysis of Survival Outcomes

10.21203/rs.3.rs-865990/v1 ◽

2021 ◽

Author(s):

Danny Conde ◽

Carlos Rey ◽

Manuel Pardo ◽

Andrea Recaman ◽

Juan Carlos Sabogal Olarte

Keyword(s):

Pancreatic Cancer ◽

Overall Survival ◽

Lymph Node ◽

Hepatic Artery ◽

Vascular Invasion ◽

Lymph Node Ratio ◽

Disease Free Survival ◽

Free Survival ◽

Node Ratio ◽

Disease Free

Abstract BackgroundAfter optimal management, 5 years survival of pancreatic cancer is 12 - 15%. Factors associated with poor prognosis are tumoral histology, harvested regional lymph nodes, and recently, hepatic artery lymph node HLA(8a) involvement. In fact, evidence has shown negative impact of node 8a involvement on overall survival and disease free-survival. Therefore, we aimed to describe the prognostic significance of the HLA(8a) lymph node metastasis in terms of disease-free survival (DFS) and overall survival (OS) on a specific cohort of patients.MethodsA retrospective study was conducted based on a prospective database from the HPB department of patients who underwent a pancreaticoduodenectomy (PD) due to pancreatic cancer during 2014 - 2021. Overall survival (OS) and disease-free survival (DFS) were estimated to be associated with positive HLA(8a) using Kaplan-Meier analysis. Log Rank test and Cox proportional hazards regression analysis were used. Results111 patients were included, 55,4% female. The most frequent pathology was ductal adenocarcinoma (60.3%). Positive rate of the HLA(8a) node was 21.62%. Median OS time was 25.5 months, and median DFS time was 13,8 months. Positive HLA(8a) node, the cutoff of lymph node ratio (LNR) resection, and vascular invasion showed a strong association with OS. (CoxRegression p = 0.03 HR 0.5, p 0.003 HR = 1.8, p = 0.02 HR 0.4 CI 95%). In terms of DFS, lymph node ratio cutoff, tumoral size, and vascular invasion showed a statistically significant association with the outcome (p = 0.008, HR = 1.5; p= 0.04 HR=2.1; p=0.02 HR=0.4 CI 95%).Conclusion In this series of pancreaticoduodenectomies, OS and DFS are significantly reduced in patients with HLA(8a) node compromise in patients with pancreatic cancer. In multivariate analysis, lymph node status remains an independent predictor of OS and DFS. Further studies are needed.

Download Full-text

Prognostic value of lymph node ratio in metastatic papillary thyroid carcinoma

The Journal of Laryngology & Otology ◽

10.1017/s0022215117002250 ◽

2017 ◽

Vol 132 (1) ◽

pp. 8-13 ◽

Cited By ~ 12

Author(s):

J Mansour ◽

D Sagiv ◽

E Alon ◽

Y Talmi

Keyword(s):

Lymph Node ◽

Papillary Thyroid Carcinoma ◽

Thyroid Carcinoma ◽

Prognostic Value ◽

Lymph Node Ratio ◽

Regional Recurrence ◽

Recurrence Free Survival ◽

Papillary Thyroid ◽

Free Survival ◽

Node Ratio

AbstractObjective:Cervical metastases in papillary thyroid carcinoma are associated with increased recurrence. However, their effect on survival remains controversial. This study evaluated literature on the prognostic value of lymph node ratio for loco-regional recurrence and survival in metastatic papillary thyroid carcinoma.Methods:The PubMed database was systematically searched using the terms ‘papillary thyroid carcinoma’ and ‘lymph node ratio’. Articles addressing the association between lymph node ratio and loco-regional recurrence or survival were identified.Results:Nine retrospective studies were included, comprising 12 400 post-thyroidectomy and neck dissection papillary thyroid carcinoma patients (median age, 48.6 years; 76 per cent females). Lymph node ratio was associated with worse recurrence-free survival in 60 and 75 per cent of studies investigating the effect of central compartment metastases and both central and lateral compartment metastases on recurrence-free survival, respectively. One large population-based study showed an association between lymph node ratio and disease-specific mortality in N1nodal disease, but failed to maintain the same association when N1bpatients were excluded.Conclusion:Regional lymph node ratio is an independent predictor for loco-regional recurrence in pathologically staged N1patients with papillary thyroid carcinoma. Patients with a high lymph node ratio should be closely followed up.

Download Full-text

Breast cancer preoperative 18FDG-PET, overall survival prognostic separation compared with the lymph node ratio

Breast Cancer ◽

10.1007/s12282-021-01234-z ◽

2021 ◽

Author(s):

Vincent Vinh-Hung ◽

Hendrik Everaert ◽

Olena Gorobets ◽

Hilde Van Parijs ◽

Guy Verfaillie ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Lymph Node ◽

Lymph Node Ratio ◽

18Fdg Pet ◽

Node Ratio

Download Full-text

A comparison of lymph node ratio with AJCC lymph node status for survival after resection for pancreatic adenocarcinoma

HPB ◽

10.1016/j.hpb.2020.11.650 ◽

2021 ◽

Vol 23 ◽

pp. S258

Author(s):

Y. Essaji

Keyword(s):

Lymph Node ◽

Pancreatic Adenocarcinoma ◽

Lymph Node Ratio ◽

Lymph Node Status ◽

Node Status ◽

Node Ratio

Download Full-text

Comparison of Survival Outcomes for Axillary Surgery Extent Based on Intraoperative Sentinel Lymph Node Biopsy Result After Neoadjuvant Chemotherapy for Breast Cancer

10.21203/rs.3.rs-273920/v1 ◽

2021 ◽

Author(s):

Jung Whan Chun ◽

Jisun Kim ◽

Il Yong Chung ◽

Beom Seok Ko ◽

Hee Jeong Kim ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Lymph Node ◽

Sentinel Lymph Node ◽

Neoadjuvant Chemotherapy ◽

Axillary Recurrence ◽

Recurrence Free Survival ◽

Free Survival ◽

Axillary Surgery ◽

Distant Metastasis Free Survival

Abstract PurposeTo investigate the survival difference between limited axillary surgery and full axillary lymph node dissection (ALND) in patients with 1-3 positive sentinel lymph node biopsies (SLNBs) after neoadjuvant chemotherapy (NAC).MethodWe retrospectively analyzed data from 676 patients who underwent surgery between 2007 and 2017 with cT1-4, cN0-3, cM0 breast cancer at the time of diagnosis and 1-3 positive SLNBs after NAC. The patients received either SLNB only or completed level I or II ALND based on SLNB results. After propensity score matching, 483 patients who had undergone SLNB only (n=188) and ALND (n=295) were included. We examined overall survival, axillary recurrence-free survival, regional recurrence-free survival, and distant metastasis-free survival and compared them between the subgroups.ResultAt a median follow-up of 59.4 months, no significant statistical difference was observed in overall survival, axillary recurrence-free survival, regional recurrence-free survival, and distant metastasis-free survival between SLNB only and ALND. No significant differences were observed in the 5-year axillary recurrence-free survival (93.1% vs. 94.0%, hazard ratio [HR]=0.94, 95% confidence interval [CI]=0.43-2.05, p=0.876) and 5-year overall survival (97.7% vs. 97.3%, HR=1.65, 95% CI=0.58-4.65, p=0.347) between the two groups.ConclusionOur analysis suggests that SLNB alone may be a possible option for patients with 1-3 sentinel node-positive breast cancer following NAC without significant compromise of recurrence or overall survival.

Download Full-text